Literature DB >> 8028763

A method for identifying short-latency human cognitive potentials in single trials by scalp mapping.

C Tomberg1, J E Desmedt.   

Abstract

Studies of scalp-recorded brain event-related potentials in humans currently depend on the electronic averaging of many responses to the stimulus. In non-averaged single responses, it is sometimes possible to see late components such as the so-called P300, but not the shorter latency components that are much smaller and masked in background noise. We tried to identify short-latency cognitive potentials evoked by finger stimulation by comparing single trial responses that are concomitantly recorded at the contralateral and ipsilateral parietal scalp respectively. We developed a single trial topographic mapping method that proved important for assessing whether any left-right difference at short latency indeed reflected genuine cognitive electrogeneses. These results make it possible to analyze on a trial-by-trial basis the short latency cognitive processing in somatic perception.

Entities:  

Mesh:

Year:  1994        PMID: 8028763     DOI: 10.1016/0304-3940(94)90431-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  A correlation study of averaged and single trial MEG signals: the average describes multiple histories each in a different set of single trials.

Authors:  L Liu; A A Ioannides
Journal:  Brain Topogr       Date:  1996       Impact factor: 3.020

2.  Non-averaged human brain potentials in somatic attention: the short-latency cognition-related P40 component.

Authors:  C Tomberg; J E Desmedt
Journal:  J Physiol       Date:  1996-10-15       Impact factor: 5.182

3.  Riemannian classification of single-trial surface EEG and sources during checkerboard and navigational images in humans.

Authors:  Cédric Simar; Robin Petit; Nichita Bozga; Axelle Leroy; Ana-Maria Cebolla; Mathieu Petieau; Gianluca Bontempi; Guy Cheron
Journal:  PLoS One       Date:  2022-01-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.